Data Availability
Unavailable because informed consent for sharing patient personal information was not obtained.
Funding
S.K.K. is the primary inventor of a domestic patent for indocyanine green-macroaggregated-hyaluronic acid mixture. The other authors have no financial ties to disclose. This study was supported by National Cancer Center Grants, Republic of Korea (NCC2310622-1 and NCC2212460-1).
Author information
Authors and Affiliations
Contributions
SKK and YSJ were responsible for study concept and design; CYL, CHR, SYC, SYP, YKL, YH, EKL, YJL, SP, TSK, and THK for data acquisition; JS for data analysis and interpretation; SKK and JS for article preparation; and all authors were responsible for article editing and final approval.
Corresponding author
Ethics declarations
Ethical Approval
The study protocol was reviewed and approved by the Institutional Review Board of the National Cancer Center, which granted a waiver of informed consent due to the retrospective design of the study (IRB no. NCC2020-0228). The study was registered on cris.nih.go.kr (Identifier: KCT0008577).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kim, Sk., Seok, J., Lee, C.Y. et al. ASO Visual Abstract: The Efficacy and Safety of an Indocyanine Green-Macroaggregated Albumin-Hyaluronic Acid Mixture (LuminoMark™) for Surgical Localization of Recurrent Thyroid Cancer. Ann Surg Oncol 31, 2364–2365 (2024). https://doi.org/10.1245/s10434-024-14918-5
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-024-14918-5